VACCINATION STATUS AND COVID-19 RELATED MORTALITY: A HOSPITAL BASED CROSS SECTIONAL STUDY IN ADMITTED PATIENTS IN SOUTHWESTERN UNIVERSITY MEDICAL CENTER FROM MAY 2021 - MAY 2022

Authors

  • Glenda Marie M. Manayon, MD Author
  • Jemer Grace S. Arellano-Compuesto, MD Author

Keywords:

COVID-19 vaccine, CoronaVac, mortality, SARS-CoV-2, vaccination status, Philippines

Abstract

The effectiveness of COVID-19 vaccines observed in clinical trials may differ in real-world populations. The Philippine Department of Health launched its national COVID-19 vaccination drive on March 1, 2021, yet hospital-level evidence on vaccination status and outcomes among Filipino inpatients remains limited. To describe the demographic and clinical profiles, disease severity, and vaccination status of adult patients admitted for COVID-19, and to examine how these factors were distributed across patient outcomes. A record-based cross-sectional study was conducted at Southwestern University Medical Center, a 126-bed tertiary hospital in Cebu City. All adult patients with rT-PCR-confirmed SARS-CoV-2 infection admitted from May 1, 2021 to May 2, 2022 were included (n = 65). Data on age, sex, comorbidities, oxygen support, length of stay, final disease severity, vaccination status, and outcome (improved, died, or discharged against medical advice) were extracted and analyzed using frequencies and proportions. Most patients were aged 40–59 years (38.5%) and male (52.3%); 70.8% had comorbidities and 72.3% required oxygen on admission. Two-thirds (66.2%) were unvaccinated, 15.4% were fully vaccinated, and 4.6% were partially vaccinated. Overall, 76.9% improved and 18.5% died. Recovery was more frequent among fully vaccinated patients (90.0%) than among unvaccinated (74.4%) and partially vaccinated patients (66.7%). No deaths occurred among patients without comorbidities, patients aged 18–39 years, or those with mild or moderate disease, whereas 75.0% of critically ill patients died. Full vaccination, younger age, and absence of comorbidities were descriptively associated with more favorable outcomes among hospitalized COVID-19 patients. Because of the small sample, formal inferential testing was not possible; larger multicenter studies are needed to confirm these associations.

Author Biographies

  • Glenda Marie M. Manayon, MD

    Department of Internal Medicine

    Southwestern University Medical Center

  • Jemer Grace S. Arellano-Compuesto, MD

    Department of Internal Medicine
    Southwestern University Medical Center

References

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., … Zaks, T. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine, 384(5), 403–416. https://doi.org/10.1056/NEJMoa2035389

Caldwell, J. M., de Lara-Tuprio, E., Teng, T. R., Estuar, M. R. J. E., Sarmiento, R. F. R., Abayawardana, M., Leong, R. N. F., Gray, R. T., Wood, J. G., Le, L.-V., McBryde, E. S., Ragonnet, R., & Trauer, J. M. (2021). Understanding COVID-19 dynamics and the effects of interventions in the Philippines: A mathematical modelling study. The Lancet Regional Health – Western Pacific, 14, Article 100211. https://doi.org/10.1016/j.lanwpc.2021.100211

Chenchula, S., Karunakaran, P., Sharma, S., & Chavan, M. (2022). Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. Journal of Medical Virology, 94(7), 2969–2976. https://doi.org/10.1002/jmv.27697

Cui, J., Li, F., & Shi, Z.-L. (2019). Origin and evolution of pathogenic coronaviruses. Nature Reviews Microbiology, 17(3), 181–192. https://doi.org/10.1038/s41579-018-0118-9

Department of Health. (2020). Interim guidelines on the COVID-19 disease severity classification and management. Republic of the Philippines.

Fontanet, A., & Cauchemez, S. (2020). COVID-19 herd immunity: Where are we? Nature Reviews Immunology, 20(10), 583–584. https://doi.org/10.1038/s41577-020-00451-5

Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., Gao, H., Ge, X., Kan, B., Hu, Y., Liu, J., Cai, F., Jiang, D., Yin, Y., Qin, C., … Qin, C. (2020). Development of an inactivated vaccine candidate for SARS-CoV-2. Science, 369(6499), 77–81. https://doi.org/10.1126/science.abc1932

Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., Southern, J., Swerdlow, D. L., Jodar, L., Levy, Y., & Alroy-Preis, S. (2021). Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data. The Lancet, 397(10287), 1819–1829. https://doi.org/10.1016/S0140-6736(21)00947-8

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., … Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

Jara, A., Undurraga, E. A., González, C., Paredes, F., Fontecilla, T., Jara, G., Pizarro, A., Acevedo, J., Leo, K., Leon, F., Sans, C., Leighton, P., Suárez, P., García-Escorza, H., & Araos, R. (2021). Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. New England Journal of Medicine, 385(10), 875–884. https://doi.org/10.1056/NEJMoa2107715

Kannan, S., Shaik Syed Ali, P., & Sheeza, A. (2021). Omicron (B.1.1.529) – variant of concern – molecular profile and epidemiology: A mini review. European Review for Medical and Pharmacological Sciences, 25(24), 8019–8022. https://doi.org/10.26355/eurrev_202112_27653

Krammer, F. (2020). SARS-CoV-2 vaccines in development. Nature, 586(7830), 516–527. https://doi.org/10.1038/s41586-020-2798-3

Muthukrishnan, J., Vardhan, V., Mangalesh, S., Koley, M., Shankar, S., Yadav, A. K., & Khera, A. (2021). Vaccination status and COVID-19 related mortality: A hospital based cross sectional study. Medical Journal Armed Forces India, 77(Suppl. 2), S278–S282. https://doi.org/10.1016/j.mjafi.2021.06.034

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Jr., Hammitt, L. L., … Gruber, W. C. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 383(27), 2603–2615. https://doi.org/10.1056/NEJMoa2034577

Tanriover, M. D., Doğanay, H. L., Akova, M., Güner, H. R., Azap, A., Akhan, S., Köse, Ş., Erdinç, F. Ş., Akalın, E. H., Tabak, Ö. F., Pullukçu, H., Batum, Ö., Şimşek Yavuz, S., Turhan, Ö., Yıldırmak, M. T., Köksal, İ., Taşova, Y., Korten, V., Yılmaz, G., … Ünal, S. (2021). Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet, 398(10296), 213–222. https://doi.org/10.1016/S0140-6736(21)01429-X

Tian, W., Jiang, W., Yao, J., Nicholson, C. J., Li, R. H., Sigurslid, H. H., Wooster, L., Rotter, J. I., Guo, X., & Malhotra, R. (2020). Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. Journal of Medical Virology, 92(10), 1875–1883. https://doi.org/10.1002/jmv.26050

Weiss, S. R., & Navas-Martin, S. (2005). Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiology and Molecular Biology Reviews, 69(4), 635–664. https://doi.org/10.1128/MMBR.69.4.635-664.2005

Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar, A., Evans, D., Inglesby, P., Cockburn, J., McDonald, H. I., MacKenna, B., Tomlinson, L., Douglas, I. J., Rentsch, C. T., Mathur, R., Wong, A. Y. S., Grieve, R., … Goldacre, B. (2020). Factors associated with COVID-19-related death using OpenSAFELY. Nature, 584(7821), 430–436. https://doi.org/10.1038/s41586-020-2521-4

World Health Organization. (2021a). Evaluation of COVID-19 vaccine effectiveness: Interim guidance, 17 March 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_effectiveness-measurement-2021.1

World Health Organization. (2021b). COVID-19 clinical management: Living guidance, 25 January 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1

Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., Yuan, M.-L., Zhang, Y.-L., Dai, F.-H., Liu, Y., Wang, Q.-M., Zheng, J.-J., Xu, L., Holmes, E. C., & Zhang, Y.-Z. (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579(7798), 265–269. https://doi.org/10.1038/s41586-020-2008-3

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., & Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. The Lancet, 395(10229), 1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., Chen, H.-D., Chen, J., Luo, Y., Guo, H., Jiang, R.-D., Liu, M.-Q., Chen, Y., Shen, X.-R., Wang, X., … Shi, Z.-L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270–273. https://doi.org/10.1038/s41586-020-2012-7

Downloads

Published

2026-09-24

Issue

Vol. 1 No. 3 (2026): Journal for the Advancement of Sustainable Development Goals

Section

Articles

License

Copyright (c) 2026 Journal for the Advancement of Sustainable Development Goals

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

License Statement

Creative Commons Attribution 4.0 International License (CC BY 4.0)

All articles published in the Journal for the Advancement of Sustainable Development Goals (JASDG) are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).

Under this license, users are free to:

  • Share — copy and redistribute the material in any medium or format;

  • Adapt — remix, transform, and build upon the material for any purpose, including commercial use;

provided that appropriate credit is given to the original author(s) and the source, a link to the license is provided, and any changes made are indicated.

The licensor cannot revoke these freedoms as long as the license terms are followed.

Authors retain copyright of their work while granting JASDG the right of first publication. The published work remains freely available to readers and may be used, distributed, reproduced, and adapted by others in accordance with the terms of the CC BY 4.0 license.

For more information about this license, please visit:

https://creativecommons.org/licenses/by/4.0/

Copyright Notice

Copyright © 2026 The Author(s).

Articles published in the Journal for the Advancement of Sustainable Development Goals (JASDG) are distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, reproduction, and adaptation in any medium, provided the original author(s) and source are properly credited.

How to Cite

VACCINATION STATUS AND COVID-19 RELATED MORTALITY: A HOSPITAL BASED CROSS SECTIONAL STUDY IN ADMITTED PATIENTS IN SOUTHWESTERN UNIVERSITY MEDICAL CENTER FROM MAY 2021 - MAY 2022. (2026). Journal for the Advancement of Sustainable Development Goals, 1(3). https://jasdg.com/index.php/jasdg/article/view/122